Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

Gimme Care vs Revel RX

Two GLP-1 deals, scored on the same six factors. Gimme Care lands a Value Score of 91, Revel RX a 80. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

Gimme Care

#5 · Grade A · Best Value

Est. first month

$130/mo

Save ~90% vs brand-name
Get this deal Full Gimme Care review →
VS

Revel RX

#68 · Grade B · Good Value

Est. first month

From $89/mo (all doses, compounded)

Save ~93% vs brand-name
Get this deal Full Revel RX review →

The verdict

Better value: Gimme Care

Gimme Care takes it on Value Score, 91 to 80 an est. $130/mo first month, with no teaser step-up baked in. Revel RX isn't out of it: Shoppers who want flat-rate compounded GLP-1 from $89/mo with LegitScript-verified telehealth care.

Our #1 overall:Neither of these is our top pick — that's CoreAge Rx (Value Score 93).See why →

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealGimme CareRevel RX
Value Score91 (A)80 (B)
Est. first month$130/moFrom $89/mo (all doses, compounded)
Save vs brand-name~90%~93%
Semaglutide$130/moFrom $89/mo (all doses, compounded)
Tirzepatide$163/moFrom $155/mo (all doses, compounded)
Both moleculesYesYes
PricingFlat — no step-upFlat — no step-up
CoverageAll 50 statesCoverage not published

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

93
Lowest Real Price
90
Gimme Care: 93. Revel RX: 90.
88
No Teaser-Rate Bait
90
Gimme Care: 88. Revel RX: 90.
98
Nationwide Availability
45
Gimme Care: 98. Revel RX: 45.
92
Both Molecules
92
Gimme Care: 92. Revel RX: 92.
84
Easy Cancellation
58
Gimme Care: 84. Revel RX: 58.
82
Reputation
78
Gimme Care: 82. Revel RX: 78.

Gimme Care

Genuinely cheap on both molecules ($130 / $163) with a LegitScript-certified pharmacy and all-50-state reach.

Why it's a deal

  • Low flat price on both molecules ($130 sema / $163 tirz)
  • LegitScript-certified pharmacy
  • Available in all 50 states

The fine print

  • No brand-name option — compounded only
  • No oral/sublingual form

Revel RX

Revel RX is a Michigan-based telehealth weight-loss platform offering compounded semaglutide at $89/month and compounded tirzepatide at $155/month — flat-rate at every dose tier.

Why it's a deal

  • Industry-low flat pricing: $89/mo for compounded semaglutide and $155/mo for tirzepatide at every dose
  • LegitScript verified and BBB accredited with an A+ rating — above-average trust signals for a compounded platform
  • Named pharmacy partners: Manifest Pharmacy and Red Rock Home Pharmacy (503A + 503B facilities)
  • Free overnight cold shipping included; no hidden fees or dose-based price increases
  • Clinical review by MD Integrations, an independent medical group, before any prescription is issued

The fine print

  • States served are not publicly listed; eligible states requires completing intake to confirm coverage
  • No labs, coaching, or ongoing health support disclosed in any public materials
  • Compounded medications are not FDA-approved (site discloses this)
  • Newer brand with limited public patient reviews or Trustpilot rating
  • Pharmacy partners named but no accreditation details (PCAB, 503B cGMP) published on the site
Get the Gimme Care deal Get the Revel RX deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores Gimme Care is ranked on the Gimme Care alternatives board, and the same list for the other side is on alternatives to Revel RX.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.